The Epsilon Group

The Epsilon Group is a modeling, analytics, and simulation services company focused on improving the understanding and management of disease, with a particular emphasis on diabetes mellitus. The company develops and delivers biosimulation services and software aimed at enhancing healthcare development and delivery, serving clients in life sciences, pharmaceutical development, and healthcare settings.

The Epsilon Group's core competency is glucose-insulin metabolism, covering Type 1 Diabetes, Type 2 Diabetes (T2DM), and Pre-Diabetes. The company provides simulation and consulting services directed at the development and refinement of diabetes-specific treatments, clinical and lifestyle protocols, and monitoring devices, using specialized physiologically-based modeling software.

Key Software Products

• Type 1 Diabetes Metabolic Simulator (T1DMS): A biosimulation platform featuring an FDA-approved in silico patient population, used for physiologically-based modeling in laboratory and translational research settings.
• Diabetes Mellitus Metabolic Simulator (DMMS.R): Incorporates additional in silico populations for Type 2 Diabetes and Pre-Diabetes, extending simulation capabilities beyond Type 1 Diabetes.
• DMMS.EDU: An educational variant of the DMMS platform, supporting academic and training use cases related to diabetes metabolic simulation.

Core Capabilities

• Development of physiologically-based pharmacokinetic and pharmacodynamic (PK/PD) drug models for diabetes-related therapies.
• Testing of control algorithms within simulated physiological environments.
• Simulation of clinical trials and examination of outcomes to optimize therapy and identify non-viable solutions early in the research and development phase, reducing costs.
• Simulation of interventions and self-management strategies for diabetes and related disease processes to support care optimization.
• Consulting services for the refinement of diabetes treatments, clinical protocols, lifestyle protocols, and monitoring devices.

Markets Served

• Life Sciences and Pharma: Supporting drug development teams in modeling, simulating clinical trials, and optimizing therapeutic approaches cost-effectively during early R&D phases.
• Healthcare: Providing simulation tools to model diabetes interventions and self-management of diabetes and related disease processes.

The Epsilon Group operates at the intersection of computational modeling and diabetes research, offering both proprietary software platforms and specialized consulting services to support research, drug development, and clinical decision-making in the diabetes and metabolic disease space.